Trial Profile

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Antiandrogens; Gallium (68Ga) gozetotide
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms PSMAddition
Sponsors Novartis; Novartis Pharmaceuticals

19 Oct 2025 Results presented at Novartis media release.
19 Oct 2025 According to a Novartis Media Release, data from this trial presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025.
19 Oct 2025 Results published in the Novartis Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com